Amarin's $245,000 Profit, a Missing Keyword, and a Cancer Trial Nobody Asked About

Amarin reported on October 28, and two unrelated events landed in the same 45 minutes. The first was arithmetic: a company that peaked at $155M of quarterly revenue in 2021 printed $39.6M of third-quarter revenue and, on that, a net profit of $245,000 — less than a cent a share. The second was biological: an investigator-initiated Phase III trial in colorectal cancer liver metastases, sponsored by the University of Leeds, showed that VASCEPA cut the hazard of death by 32% in patients who had surgery — even though it failed its primary endpoint.

The market has been voting on the first and ignoring the second. Amarin's tape is a single clean downtrend over the last ninety days, -20.2%, sitting 22.6% below its July 1 high of $16.47 — and the full history is a graveyard of exactly this pattern: a -97.4% drawdown from the December 2019 peak of $482.40, punctuated by a +600% two-week move years ago that has never repeated. A thin, sub-$300M-market-cap specialty pharma reporting into a fade is a different animal than one reporting into a breakout, and this one is the former.

The profit was manufactured by subtraction

Pete Fishman did not bury the lede: “We reported our first profitable quarter in two years, reflecting the benefits of our completed restructuring as well as our company-managed U.S. and fully partnered international commercial model.” — Pete Fishman, Chief Financial Officer · 2026-10-28 That is an honest sentence, and it is also the whole story. Total operating expense fell 44% year over year, SG&A fell 27%, and restructuring charges of $9.4M simply vanished from the comparison. Strip restructuring out and opex is still down 22%. The profit is real; the business producing it is not growing.

U.S. product revenue was “$28.5 million, compared to $40.9 million in last year's third quarter” — Pete Fishman, Chief Financial Officer · 2026-10-28 — a 30% decline driven almost entirely by net selling price, not volume. Jessica Fye of JPMorgan asked the obvious question, and Aaron Berg confirmed branded volume was "relatively flat." The company holds 47% of the U.S. U.S. IPE market, and it is defending that share by paying for it in price.

Which is why the tone shift on exclusivity matters more than any number. In February, Berg was combative about keeping payer contracts through the year. On this call he reframed the whole subject as weather: “changes in product exclusivity are part of the normal cadence of our U.S. commercial business.” — Aaron Berg, President and Chief Executive Officer · 2026-10-28 And Fishman, asked about 2027, declined to promise anything: “we have seen that continued pricing pressure over previous years and would anticipate that to continue into 2027.” — Pete Fishman, Chief Financial Officer · 2026-10-28 The restructuring bought profitability; it did not buy a floor on price.

The keyword that disappeared

Here is the quiet one. For at least five consecutive quarters, the authorized generic was the analytical center of gravity at Amarin — asked by Leerink in February, asked again by Leerink in April, and answered each time with a version of “we don't believe that it's in our best interest to launch an authorized generic at this time, even though we're ready to do so when the opportunity arises.” — Aaron Berg, President and Chief Executive Officer · 2026-04-29 It ranked among the top five company keywords as recently as the second quarter.

This quarter, the authorized generic barely exists. No prepared remark, no analyst question, no keyword in the top thirty. The same is true of the milestone payment framework under the Recordati deal — a repeated question from JPMorgan in October 2025 and Leerink in April 2026, now absent. What management stopped talking about is at least as informative as what it started talking about: with U.S. price now guided to keep eroding into 2027, the AG remains the single largest unexercised cash lever the company has, and it has gone off the agenda.

Colorectal cancer is genuinely new — and genuinely unresolved

Now the other half. The top-ranked company keyword this quarter is colorectal cancer — a theme that appears nowhere in the prior twelve quarters of Amarin's keyword history. Alongside it: EPA for Metastasis Trial 2, the University of Leeds research group, and a cluster of omega-3 biology language. This is not boilerplate. It is the first new scientific story the company has had since REDUCE-IT.

while the primary endpoint of progression-free survival was not met, the study demonstrated an improvement in the key secondary endpoint of overall survival. A statistically significant 32% lower hazard of death, which is a meaningful finding in a patient population where up to 60 of patients may experience disease recurrence within two years following surgery.

Read that carefully: 448 patients, randomized, double-blind, placebo-controlled, the same formulation and dose as REDUCE-IT, and the powered primary endpoint missed. The overall-survival hit is real and statistically significant, but it is a secondary endpoint in a trial Amarin did not run and did not design. Management's own language is unusually candid about how little is settled — “we just saw the data ourselves” — Aaron Berg, President and Chief Executive Officer · 2026-10-28 — followed by a list of questions about commercial opportunity, unmet need, and intellectual property rather than a plan.

The tell is in the Q&A. Exactly two analysts asked questions before the operator closed the line: JPMorgan and Goldman Sachs. Leerink, a fixture on the last three calls, was absent. When Goldman's Paul Choi did raise "additional therapeutic applications," it was framed as a partnering question, not a valuation question. The market's answer to a 32% survival benefit was silence, and the stock's answer was a 20% ninety-day slide. That is not disbelief in the data; it is disbelief that the data converts into cash within any estimable window.

Below cash, with an advisor and no clock

The balance sheet is the counterweight to everything above. Cash and investments of $324M, up $21M from year-end, zero debt, four consecutive quarters of positive operating cash flow ($9M in Q3, $22M through nine months versus a $9M outflow a year ago), inventory down 31% since Q4 2024, and liabilities at just 28.9% of assets. Effective net cash stands at $315M — against a market capitalization of roughly $264M. The market is valuing the entire commercial enterprise, the European royalty stream, and the colorectal optionality at less than nothing.

Which makes the strategic-review paragraph the most important one on the call, and the softest. In April, Berg described a buyback as something that “is being discussed and could possibly happen at the right time” — Aaron Berg, President and Chief Executive Officer · 2026-04-29. On Wednesday it became conditional on an outside process:

we continue to work closely with Barclays, our exclusive financial advisor, and remain focused on working through these efforts in a timely and disciplined manner. These discussions and their potential outcomes will inform the timing, scale, and prioritization of future capital deployment activities, such as a share repurchase.

The exclusive adviser relationship has now spanned at least three quarters of calls without a transaction, a timetable, or a stated scope. Meanwhile the operational story rests on market demand growth abroad — Europe in-market up an estimated 68%, Rest of World 46%, global 55% — a metric that management has had to re-explain every single quarter because it does not equal reported revenue. Europe product revenue actually fell, to $3.7M from $4.1M. The end market demand versus product revenue gap is now a permanent feature of the equity story, not a transition quarter.

The bull case is simple and uncomfortable: a debt-free company with $324M of cash, a profitable-and-shrinking U.S. franchise generating real cash, a partner-driven international royalty that grows double digits in-market, and a scientifically interesting if commercially unformed cancer signal — all trading below liquidation value, with an advisor already retained. The bear case is that every source of upside requires someone else's decision: a payer's formulary, Recordati's order timing, the University of Leeds' next trial, or Barclays' next phone call. This quarter, Amarin finally produced a new idea. It still hasn't produced a new decision.